According to experts at the Dana-Farber Cancer Institute, a diabetes drug in common use could dramatically boost how effective a platinum-base cancer drug is. Conducting experiments involving mice, the research team combined diabetic medication rosiglitazone with a platinum chemotherapy agent, to startling results.
The scientists found that the dual drugs reduced mouse tumours as much as three times more effectively than either of the individual drugs. Results of the study were published in the article Cancer Cell.
Depending on its efficiency amongst humans, the combo drug could have a role to play in the treatment of ovaria, lung and other cancers. Bruce Speigelma, the senior author, reportedly commented: “There’s still a huge gulf between these experiments and human cancers. But it’s worked in every animal model of cancer we’ve looked at, and I think there’s a fair chance it will help people.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…